Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 2, Pages e1071007
Publisher
Informa UK Limited
Online
2015-08-12
DOI
10.1080/2162402x.2015.1071007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
- (2014) A. M. Di Giacomo et al. ANNALS OF ONCOLOGY
- Immunotherapy for prostate cancer: recent developments and future challenges
- (2014) Michael T. Schweizer et al. CANCER AND METASTASIS REVIEWS
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Expression of stress ligands of the immunoreceptor NKG2D in melanoma: Regulation and clinical significance
- (2014) Annette Paschen et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy
- (2014) Erika Rijavec et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
- (2013) J. D. Wolchok et al. ANNALS OF ONCOLOGY
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
- (2013) Y. P. de Coana et al. Cancer Immunology Research
- Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
- (2013) S. Kitano et al. Cancer Immunology Research
- Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells
- (2013) Amandine Legat et al. Frontiers in Immunology
- Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
- (2012) L. G. Radvanyi et al. CLINICAL CANCER RESEARCH
- Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
- (2012) Ahmad A. Tarhini et al. JOURNAL OF IMMUNOTHERAPY
- Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
- (2012) Wenshi Wang et al. Journal of Translational Medicine
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
- (2011) Jianda Yuan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Th17 cells: positive or negative role in tumor?
- (2010) Yuqiang Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- (2010) Axel Hoos et al. SEMINARS IN ONCOLOGY
- Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications
- (2010) Luana Calabrò et al. SEMINARS IN ONCOLOGY
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
- (2010) Margaret K. Callahan et al. SEMINARS IN ONCOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors
- (2008) Cristina Maccalli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
- (2008) C. Menard et al. CLINICAL CANCER RESEARCH
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More